The use of beta-adrenergic blockers in the treatment of angina and hypertension.
During the past decade, beta-adrenoreceptor blocking agents have proved to be valuable assets in our therapeutic armamentarium for management of both angina pectoris and essential hypertension. In ischemic heart disease, these agents reduce myocardial oxygen requirements by decreasing the force of myocardial contraction and by reducing heart rate. Consequently, decreased blood supply to portions of the myocardium is tolerated better. The beta-blockers are effective in reducing the frequency and severity of episodes of angina pectoris and in extending exercise tolerance. If needed, additional benefit may be gained by adding long-acting nitrates, or calcium-channel blockers or both.
Caris
T N
TN
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009928:Organ Specificity; D012995:Solubility; D013566:Sympathomimetics
D000319:Adrenergic beta-Antagonists; D013566:Sympathomimetics